Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma

Molecular Carcinogenesis

Volumn 52, Issue 7, 2013, Pages 568-579

  Ping, Szu Yuan ^a   Shen, Kun Hung ^b   Yu, Dah Shyong ^c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cancer progression; DNA methylation; Urothelial cell carcinoma; VEGF A

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; METHYL CPG BINDING PROTEIN 2; VASCULOTROPIN A;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; DNA METHYLATION; DOWN REGULATION; GENE SEQUENCE; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA;

BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASM GRADING; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879459728     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21892     Document Type: Article

References (47)

1. Mian BM, Dinney CP, Bermejo CE, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappa B. Clin Cancer Res 2003; 8: 3167- 3175.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2011; 61: 113- 114.
3. Fauconnet S, Lascombe I, Chabannes E, et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002; 277: 23534- 23543.
4. Izawa JI, Sweeney P, Perrotte P, et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002; 8: 1258- 1270.
5. Kausch I, Bohle A. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol 2002; 41: 15- 29.
6. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327- 336.
7. Philp EA, Stephenson TJ, Reid MWR. Prognostic significance of angiogenesis in transitional cell carcinoma of the human bladder. Br J Urol 1996; 77: 352- 357.
8. Dinney CP, Fishbeck R, Singh RK, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995; 154: 1532- 1538.
9. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249- 257.
10. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255- 1262.
11. Chabannes E, Bernardini S, Wallerand H. Angiogenesis in bladder: Prognosis indicator and therapeutic target. Prog Urol 2001; 11: 417- 427.
12. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55: 510- 513.
13. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669- 676.
14. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000; 6: 2431- 2439.
15. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001; 80: 181- 188.
16. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6: 2803- 2807.
17. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000; 36: 748- 753.
18. Linderholm BK, Gruvberger-Saal S, Fernö M, Bendahl PO, Malmström P. Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer 2002; 98: 228- 233.
19. Schmidt M, Voelker HU, Kapp M, Dietl J, Kammerer U. Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage. Anticancer Res 2008; 28: 1719- 1724.
20. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57: 5281- 5285.
21. Enokida H, Nakagawa M. Epigenetics in bladder cancer. Int J Clin Oncol 2008; 13: 298- 307.
22. Karam JA, Fan J, Stanfield J, et al. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer 2007; 15: 1795- 1802.
23. Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett 2010; 15: 131- 137.
24. Zhang S, Zeng F, Peng S, Zhu C, Li H, Wang L. Effects on biological behavior of bladder carcinoma T24 cells via silencing DNMT1 and/or DNMT3b with shRNA in vitro. J Huazhong Univ Sci Technolog Med Sci 2009; 29: 215- 219.
25. Wu G, Guo Z, Chang X, et al. LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. Cancer Res 2007; 1: 4123- 4129.
26. Cowled P, Kanter I, Leonardos L, Jackson P. Uroplakin Ib gene transcription in urothelial tumor cells is regulated by CpG methylation. Neoplasia 2005; 7: 1091- 1103.
27. Derleth C, Mayer IA. Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer 2010; 10: E23- E31.
28. Winder T, Lenz HJ. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology 2010; 6: 2163- 2176.
29. Gschwend JE. Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma. Onkologie 2010; 33: 10- 11.
30. Mǎrgǎritescu C, Pirici D, Simionescu C, et al. VEGF and VEGFRs expression in oral squamous cell carcinoma. Rom J Morphol Embryol 2009; 50: 527- 548.
31. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003; 9: 677- 684.
32. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Gene Dev 2001; 11: 293- 299.
33. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830- 5835.
34. Theodoropoulos VE, Lazaris ACh, Sofras F, et al. Hypoxia inducible factor-1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004; 46: 200- 208.
35. Theodoropoulos VE, Lazaris AC, Kastriotis I, et al. Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumor recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 2005; 95: 425- 431.
36. Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18: 185- 197.
37. Marsit CJ, Houseman EA, Christensen BC, et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS ONE 2010; 5: e12334.
38. Lin RK, Wu CY, Chang JW, et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010; 14: 5807- 5817.
39. Deng T, Zhang Y. Possible involvement of activation of P53/P21 and demethylation of RUNX 3 in the cytotoxicity against Lovo cells induced by 5-Aza-2′-deoxycytidine. Life Sci 2009; 84: 311- 320.
40. Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol 2009; 19: 77.
41. Chikazawa M, Inoue K, Fukata S, Karashima T, Shuin T. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology 2008; 6: 335- 345.
42. Nadaoka J, Horikawa Y, Saito M, et al. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer 2008; 122: 1297- 1302.
43. Nourbakhsh M, Kalble S, Dorrie A, Hauser H, Resch K, Kracht M. The NF-kappa b repressing factor is involved in basal repression and interleukin (IL)-1-induced activation of IL-8 transcription by binding to a conserved NF-kappa β-flanking sequence element. J Biol Chem 2001; 276: 4501- 4508.
44. Toki K, Enokida H, Kawakami K, et al. CpG hypermethylation of cellular retinol-binding protein 1 contributes to cell proliferation and migration in bladder cancer. Int J Oncol 2010; 37: 1379- 1388.
45. Huang YC, Hung WC, Chen WT, Jiang WH, Yu HS, Chai CY. Effects of MEK and DNMT inhibitors on arsenic-treated human uroepithelial cells in relation to cyclin-D1 and p16. Toxicol Lett 2010; 200: 59- 66.
46. Lorincz MC, Dickerson DR, Schmitt M, Groudine M. Intragenic: DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol 2004; 11: 1068- 1075.
47. Berger J, Bird A. Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans 2005; 33: 1537- 1540.